MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2024 International Congress

September 27-October 1, 2024. Philadelphia, PA.

View by Title View Sessions
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • NouvNeu001, A Phase 1 Stage Chemically Induced Human Dopaminergic Progenitor Cell Therapy for the Treatment of Mid- to Late-stage Parkinson’s Disease

    M. Cai, J. Wei, X. Ren, R. Yan, H. Chen, N. Xiong (Wuhan, China)

  • Novel ASO Targeting IGHMBP2 Cryptic Splice Variant: Efficacy and Safety

    S. Smieszek, B. Przychodzen, C. Tyner, C. Johnson, C. Polymeropoulos, G. Birznieks, M. Polymeropoulos (Washington, USA)

  • Novel In-Clinic Use of Levodopa Inhalation Powder (CVT-301) as an Outpatient Diagnostic Tool for Parkinson’s Disease

    Z. Afshari, N. Nguyen, M. Afshari (Glenview, USA)

  • Novel Partial Gene Deletion in CaCNA1A Presenting with Gait Ataxia, Vertigo, and Abnormal Eye Movements

    D. Mohanty, I. Bledsoe (San Francisco, USA)

  • Nutritional Status Implication at 6 Months in Parkinson’s Disease: Follow-Up Results

    N. Ayo Mentxakatorre, B. Tijero, T. Fernandez-Valle, A. Ortiz-de-Echevarria, M. Acera Gil, I. Chavarri Rubio, C. Juanes Moreno, M. Ruiz-Lopez, JC. Gomez-Esteban, R. Del Pino (Barakaldo, Spain)

  • Obsessive-Compulsive Disorder Prevalence in Parkinson’s Disease Caregivers

    F. Hojjatipour, M. Salari (tehran, Islamic Republic of Iran)

  • Oculomotor Biomarkers for Cerebellar Ataxia and Severity in Smooth Pursuit

    P. Ponger, G. Gurevich, R. Alcalay, Y. Bonneh, S. Shani (Tel Aviv, Israel)

  • Odor-specific symptoms in Parkinson’s disease – UPSIT odor identification status versus clinical severity.

    YG. Guo, SC. Chiu (Taichung, Taiwan)

  • Once-Daily Suvecaltamide Pharmacokinetics, Safety, & Tolerability–Phase 1, Randomized, Double-Blind, Multiple Ascending Dose Study

    S. Markova, M. Baladi, M. Lee, C. Chen (Palo Alto, USA)

  • One dose fits all? An analysis of the levodopa equivalent dose over time in Parkinson’s disease

    V. Lavu, J. Dwarampudi, Q. Yuan, F. Sarmento, T. de Araujo, V. Garg, J. Wong (Gainesville, USA)

  • « Previous Page
  • 1
  • …
  • 115
  • 116
  • 117
  • 118
  • 119
  • …
  • 181
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
        • Help & Support
        • About Us
        • Cookies & Privacy
        • Wiley Job Network
        • Terms & Conditions
        • Advertisers & Agents
        Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
        Wiley